- Home
- RPRX vs MBLY Comparison
RPRX vs MBLY Comparison
Compare RPRX & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- MBLY
- Stock Information
- Founded
- RPRX 1996
- MBLY 1999
- Country
- RPRX United States
- MBLY Israel
- Employees
- RPRX N/A
- MBLY N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- MBLY Computer Software: Prepackaged Software
- Sector
- RPRX Health Care
- MBLY Technology
- Exchange
- RPRX Nasdaq
- MBLY Nasdaq
- Market Cap
- RPRX 14.2B
- MBLY 11.8B
- IPO Year
- RPRX 2020
- MBLY 2022
- Fundamental
- Price
- RPRX $34.02
- MBLY $15.96
- Analyst Decision
- RPRX Strong Buy
- MBLY Buy
- Analyst Count
- RPRX 4
- MBLY 20
- Target Price
- RPRX $42.50
- MBLY $19.33
- AVG Volume (30 Days)
- RPRX 3.9M
- MBLY 3.3M
- Earning Date
- RPRX 05-08-2025
- MBLY 04-24-2025
- Dividend Yield
- RPRX 2.59%
- MBLY N/A
- EPS Growth
- RPRX 37.60
- MBLY N/A
- EPS
- RPRX 2.45
- MBLY N/A
- Revenue
- RPRX $2,263,845,000.00
- MBLY $1,853,000,000.00
- Revenue This Year
- RPRX $31.16
- MBLY $7.26
- Revenue Next Year
- RPRX $5.86
- MBLY $14.94
- P/E Ratio
- RPRX $13.85
- MBLY N/A
- Revenue Growth
- RPRX 1.13
- MBLY N/A
- 52 Week Low
- RPRX $24.05
- MBLY $10.48
- 52 Week High
- RPRX $34.20
- MBLY $33.26
- Technical
- Relative Strength Index (RSI)
- RPRX 61.77
- MBLY 58.03
- Support Level
- RPRX $32.18
- MBLY $16.39
- Resistance Level
- RPRX $34.11
- MBLY $17.49
- Average True Range (ATR)
- RPRX 0.82
- MBLY 0.66
- MACD
- RPRX 0.09
- MBLY 0.19
- Stochastic Oscillator
- RPRX 91.93
- MBLY 54.11
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.